Effects of Yogurt With Probiotics in Adults With Type 2 Diabetes Mellitus
Launched by FACULTY OF MEDICAL SCIENCES, CLINICAL HOSPITAL · Jul 26, 2021
Trial Information
Current as of May 14, 2025
Completed
Keywords
ClinConnect Summary
After being informed about the study and the potential risks, all patients who gave their written informed consent underwent a screening period of 1 week to determine their eligibility to participate in the study. At week 0, patients who met the eligibility requirements were randomized in a double-blind manner (participant and investigator) to the American Diabetes Association (ADA) diet + yogurt with premium probiotics (300 g/d) or ADA diet + conventional yogurt (300 g/d) or ADA diet without fermented dairy.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with T2DM diagnosed at least one year ago.
- • That they are outpatients.
- • Between 25 and 65 years old.
- Exclusion Criteria:
- • Smoking patients.
- • Lactose intolerance.
- • Pregnancy or breastfeeding.
- • Presence of kidney, liver, immunodeficiency, inflammatory bowel disease or thyroid disorder.
- • Use of insulin, estrogen, progesterone or diuretic injections.
- • Consumption of probiotic supplements two months before the start of the study
About Faculty Of Medical Sciences, Clinical Hospital
The Faculty of Medical Sciences at the Clinical Hospital is a leading academic institution dedicated to advancing healthcare through innovative research and clinical trials. With a commitment to excellence in patient care and medical education, the faculty collaborates with a network of healthcare professionals and researchers to conduct rigorous studies that aim to improve treatment outcomes and enhance medical knowledge. By integrating cutting-edge methodologies and interdisciplinary approaches, the Faculty of Medical Sciences strives to contribute significantly to the fields of medicine and public health, ensuring that findings translate into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cordoba, , Spain
Patients applied
Trial Officials
Pablo Perez Martinez, MD
Study Director
Instituto Maimonides de Investigacion Biomedica de Cordoba, Spain
Maria Ruiz Diaz Narvaez, DN
Principal Investigator
Faculty of Medical Science, Paraguay
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials